medigraphic.com
SPANISH

Revista Cubana de Hematología, Inmunología y Hemoterapia

ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2015, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (4)

Apheresis procedures at the Institute of Hematology and Immunology

González ST, Fernández DN, Salgado AO, González IAI, Román TR, de la Cruz ZN
Full text How to cite this article

Language: Spanish
References: 21
Page: 434-443
PDF size: 128.24 Kb.


Key words:

apheresis, production, therapeutic, plasmapheresis, exchange transfusion, leukocytapheresis, thrombocytapheresis.

ABSTRACT

Introduction: in recent decades, interest in apheresis has increased due to advances in technology that have made them available to health professionals with access to specific equipment, safety, effectiveness and speed to perform these procedures in terms of transfusion and therapeutics.
Objective: to present the experience gained at the Institute of Hematology and Immunology in performing different types of apheresis.
Methods: adescriptive retrospective study was performed which included all patients who underwent an apheresis procedure between January 2008 and December 2013. Variables were: patient´s general data, the establishment of provenance, method where analyzed apheresis was performed, method used, and diseases requiring the proceeding.
Results: 3 332 apheresis proceedings were done : 1 057 for production with thrombopheresis prevalence which ranked 96,68%. Of the 1 078 therapeutic apheresis performed, the first place went to plasmapheresis with 26,5 %, followed by exchange transfusions (15,8 %); 1 197 apheresis of mononuclear cells and platelets to be used in regenerative medicine were also conducted.
Conclusions: the results of this preliminary study show the gradual development in the use of apheresis procedures in our institution, with both production and therapy aims, which not only allows the diffusion of production of components by apheresis which provides physicians and patients in need of blood products with higher quality and security replacement therapy, but also provides knowledge about the actual possibilities for alternative therapy in some diseases.


REFERENCES

  1. Pham HP and Schwartz J. Overview of Therapeutic Apheresis. In: Shaz BH, Hillyer CD, Rosbal M and Abrams CS Eds. Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects. 2da Ed. Amsterdam:Elsevier;2013. p. 467-80.

  2. Bravo-Lindoro A, Méndez-Jácome DL, Medina-Macías ML, Béjar-Ramírez Y, Sánchez-Guerrero S. Aféresis Terapéutica. Rev Med Inst Mex Seguro Soc. 2006;44 (Supl 2):77-80.

  3. Ballester JM, Alfonso ME, Bencomo AA, Castillo D, Cortina L, López de Roux MR, et al. ABC de la Medicina Transfusional: Guías Clínicas. La Habana: Instituto de Hematología e Inmunología, Comisión Nacional de Sangre, Organización Panamericana de la Salud. 2006.

  4. Fernández-Delgado ND, Forrellat-Barrios M, González-Suárez T, Salgado-Arocena O. Plasmaféresis terapéutica. Análisis de 2 años en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2012 Jun [citado 2014 Oct 27];28(2): 151-68.

  5. McLeod BC. Therapeutic apheresis: history, clinical application, and lingering uncertainties. Transfusion. 2010 Jul;50(7):1413-26. doi:10.1111/j.1537- 2995.2009.02505.x.

  6. Szczepiorkowski ZM, Winter JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher. 2010;25: 83-177.

  7. Shaz BH, Schwart J and Winters JL. How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedure. Transfusion. 2014 Jan;54:17-25. DOI:10.1111/trf.12499

  8. Hernández-Ramírez P. Reflexiones sobre la introducción y desarrollo de la terapia celular en Cuba. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet].2013 [citado 2014 Oct 27];29 (3):Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/83/68

  9. Ballester JM, Alfonso ME, Ballester L, Bencomo AA, Cortina L, Macías C, et al. Procederes de bancos de sangre y servicios de transfusiones. La Habana: Instituto de Hematología e Inmunología, Organización Panamericana de la Salud. 2004.

  10. Cortina- Rosales L , Hernández- Ramírez P , López- De Roux MR , Artaza- Sanz H M, Dorticós- Balea E , Macías- Abraham C , et al. Aislamiento de células mononucleares de sangre periférica para trasplante de células madre: Método simplificado. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2008 [citado 2014 Oct 27];24 (3):Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892008000300004&lng=es&nrm=iso&tlng=es

  11. Quintana-González S. Recolección de multicomponentes por aféresis. Gac Méd Méx. 2003;139 (supl 3):151-4.

  12. Schwartz J, Winters JL, Padmanabhan A. Guidelines on the use of therapeutic apheresis in clinical practice– evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013;28:145-284.

  13. Monteiro-Ribeiro R, Almeida de Brito MV, Cibeli -da Silva Fava F, Ferreira AM, Freire- Arcanjo Silva H, Caxilé- Barnosa JP. Experiência em aférese terapêutica no Serviço de hemoterapia do HEMOCE. Hemasferio. 2009 Mar;10:10-2.

  14. Shahidi S, Memarzadeh M, Kamali M, Naini AE. Trend of indications for therapeutic plasma exchange at an Iranian University Hospital. Transfus Apher Sci. 2011;44:119-22. doi:10.1016/j.transci.2011.01.003.

  15. Martínez Grau Isabel. Inmunoglobulina intravenosa: sus aplicaciones. Rev Cubana Invest Bioméd. 2003 Dic;22(4):259-66.

  16. Pham HP and Schwartz J. Therapeutic Erythrocytapheresis. In: Shaz BH, Hillyer CD, Rosbal M, Abrams CS eds. Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects. 2da Ed. Amsterdam: Elsevier;2013. p. 505-8.

  17. Shi PA. Transfusion Management in patients with Hemoglobinophaties. In: Shaz BH, Hillyer CD, Rosbal M, Abrams CS eds. Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects. 2da Ed. Amsterdam: Elsevier;2013. p. 327-36.

  18. Drasar E, Igbineweka N, Vasavda N, Free M, Awogbade M, Allman M et al. Blood transfusion usage among adults with sickle cell disease – a single institution experience over ten years. Br J Haematol. 2011 March;152, (6):766–70. DOI:10.1111/j.1365-2141.2010.08451.x

  19. Pham HP and Schwartz J. Therapeutic Leukocytapheresis and adsorptive Cytapheresis. In: Shaz BH, Hillyer CD, Rosbal M, Abrams CS eds. Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects. 2da Ed. Amsterdam: Elsevier; 2013. p. 511-4.

  20. Pham HP and Schwartz J. Therapeutic Thrombocytapheresis. In: Shaz BH, Hillyer CD, Rosbal M, Abrams CS eds. Transfusion Medicine and Hemostasis. Clinical and Laboratory Aspects. 2da Ed. Amsterdam: Elsevier;2013. p. 509-11.

  21. Hernández-Ramírez P, Forrellat-Barrios M. Ventajas de la terapia celular con células mononucleares derivadas de la médula ósea, aplicadas en su conjunto. Rev Cubana Hematol Inmunol Hemoter. 2013 Dic;29(4):407-12.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Cubana Hematol Inmunol Hemoter . 2015;31